عرض بسيط للتسجيلة

المؤلفMehta, Khyati Y.
المؤلفWu, Hung-Jen
المؤلفMenon, Smrithi S.
المؤلفFallah, Yassi
المؤلفZhong, Xiaogang
المؤلفRizk, Nasser
المؤلفUnger, Keith
المؤلفMapstone, Mark
المؤلفFiandaca, Massimo S.
المؤلفFederoff, Howard J.
المؤلفCheema, Amrita K.
تاريخ الإتاحة2017-10-04T10:22:06Z
تاريخ النشر2017-09-15
اسم المنشورOncotarget
المعرّفhttp://dx.doi.org/10.18632/oncotarget.20324
الاقتباسKhyati Y. Mehta, Hung-Jen Wu, Smrithi S. Menon, Yassi Fallah, Xiaogang Zhong, Nasser Rizk, Keith Unger, Mark Mapstone, Massimo S. Fiandaca, Howard J. Federoff, and Amrita K. Cheema. "Metabolomic biomarkers of pancreatic cancer: a meta-analysis study" Oncotarget (2017) volume 8, issue 40, pp. 68899-68915
معرّف المصادر الموحدhttp://hdl.handle.net/10576/5666
الملخصPancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is no blood test for early detection and diagnosis of this disease. Several research groups have reported on metabolomics based clinical investigations to identify biomarkers of PC, however there is a lack of a centralized metabolite biomarker repository that can be used for meta-analysis and biomarker validation. Furthermore, since the incidence of PC is associated with metabolic syndrome and Type 2 diabetes mellitus (T2DM), there is a need to uncouple these common metabolic dysregulations that may otherwise diminish the clinical utility of metabolomic biosignatures. Here, we attempted to externally replicate proposed metabolite biomarkers of PC reported by several other groups in an independent group of PC subjects. Our study design included a T2DM cohort that was used as a non-cancer control and a separate cohort diagnosed with colorectal cancer (CRC), as a cancer disease control to eliminate possible generic biomarkers of cancer. We used targeted mass spectrometry for quantitation of literature-curated metabolite markers and identified a biomarker panel that discriminates between normal controls (NC) and PC patients with high accuracy. Further evaluation of our model with CRC, however, showed a drop in specificity for the PC biomarker panel. Taken together, our study underscores the need for a more robust study design for cancer biomarker studies so as to maximize the translational value and clinical implementation.
راعي المشروعThis work was supported by ACS IRG-92-152-17 pilot award number AWD4470404 to KU and AKC. The authors would like to acknowledge the Metabolomics Shared Resource in Georgetown University (Washington DC, USA) partially supported by NIH/NCI/CCSG grant P30-CA051008
اللغةen
الناشرImpact Journals
الموضوعpancreatic cancer
Metabolomic
biomarkers
العنوانMetabolomic biomarkers of pancreatic cancer: a meta-analysis study
النوعArticle
الصفحات68899-68915
رقم العدد40
رقم المجلد8
ESSN1949-2553
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة